NovoCure (NVCR) Notes Payables (2024 - 2025)
NovoCure (NVCR) posted quarterly Notes Payables of $560.6 million for Q3 2025, up 0.59% year-on-year from $557.3 million in Q3 2024, and little changed on a QoQ basis from $559.8 million in Q2 2025.
NovoCure (NVCR) Notes Payables (2024 - 2025) Analysis & Trends
NovoCure (NVCR) has reported Notes Payables for 2 consecutive years, with $560.6 million the latest figure, recorded in Q3 2025.
- Quarterly Notes Payables rose 0.59% year-over-year to $560.6 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $560.6 million (up 0.59% YoY) and the FY2024 annual result came in at $558.2 million, changed N/A from the prior year.
- Notes Payables steadied at $560.6 million in Q3 2025 per NVCR's latest filing, from $559.8 million in the prior quarter.
- Over the last five years, Notes Payables for NVCR reached as high as $560.6 million in Q3 2025 and fell as low as $557.3 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn |
| 10 | NovoCure | 1.97 Bn | 1.53 Bn | 142.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 560.62 Mn |
| Jun 30, 2025 | 559.79 Mn |
| Mar 31, 2025 | 558.97 Mn |
| Dec 31, 2024 | 558.16 Mn |
| Sep 30, 2024 | 557.33 Mn |